Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PM(NOC) Regulations: Five-year Anniversary Of Major Amendments

09/28/2022 | 08:10am EST

September 21, 2022, marked the fifth anniversary of the significant amendments to the Patented Medicines (Notice of Compliance) Regulations (Regulations). This article provides an update on activities in the fifth year following the amendments, including new actions and a wave of Court decisions, both on the merits and procedural (see our prior first, second, third and fourth anniversary updates).

Status of actions under the Regulations

In the period of September 21, 2021 to September 21, 2022, approximately 29 sets1 (40 total) of actions were started. A comparison to previous years is provided below:2


Of the approximately 221 actions started since the amendments, the majority continue to be resolved prior to completion of the trial (155, in grey below). 26 actions were pursued to a decision on the merits; the innovator was successful in 12. Since some of the actions were tried and decided in a single set of reasons, there are 15 decisions on the merits, nine of which were in favour of the innovator. Appeals are pending from eight decisions on the merits; four trial decisions were affirmed on appeal.


The following 19 drugs have at least one action ongoing:

  • adalimumab (AbbVie's HUMIRA)
  • aflibercept (Bayer's EYLEA)
  • bimatoprost (Allergan's LUMIGAN RC)
  • carfilzomib (Amgen's KYPROLIS)
  • dexlansoprazole (Takeda's DEXILANT)
  • efinaconazole (Bausch's JUBLIA)
  • empagliflozin (Boehringer's JARDIANCE)
  • emtricitabine, rilpivirine, tenofovir alafenamide (Gilead's ODEFSEY)
  • ibrutinib (Janssen's IMBRUVICA)
  • linagliptin (Boehringer's TRAJENTA)
  • nintedanib (Boehringer's OFEV)
  • paliperidone palmitate (Janssen's INVEGA SUSTENNA)
  • riociguat (Bayer's ADEMPAS)
  • sacubitril/valsartan (Novartis' ENTRESTO)
  • selexipag (Janssen's UPTRAVI)
  • sitagliptin and metformin hydrochloride (Merck's JANUMET)
  • tenofovir alafenamide (Gilead's VEMLIDY)
  • tenofovir alafenamide/emtricitabine (Gilead's DESCOVY)
  • vortioxetine (Lundbeck's TRINTELLIX)
  • In the last year, Apotex was the most active patent challenger (defendant in 17 actions relating to seven drugs), followed by a tie for second between JAMP Pharma and Sandoz, each with five actions relating to five drugs.

    In addition, in the past year, four actions were commenced further to section 8.2 (for a total of 17 commenced since the amendments to the Regulations). Section 8.2 permits a first person/patentee to bring an infringement action asserting a patent not listed on the Patent Register once served with a Notice of Allegation (NOA). Only the four actions started in the past year are ongoing, relating to:

  • efinaconazole (Bausch's JUBLIA)
  • sitagliptin and metformin hydrochloride (Merck's JANUMET)
  • aflibercept (Bayer's EYLEA)
  • In general, trials of section 8.2 proceedings have been scheduled approximately three to four months after the trial of the section 6 proceedings. None have yet proceeded to trial.

    Three actions pursuant to section 8 of the Regulations were commenced in the past year (for a total of eight started under the amended Regulations, though only five are pending) seeking damages following unsuccessful patent infringement actions:

  • fampridine (commenced by Pharmascience and separately Taro Pharmaceuticals)
  • abiraterone (commenced by Pharmascience)
  • To date, there have been no decisions on the merits of a section 8 action under the amended Regulations. The first trials are scheduled for June 2023 (Apotex and Dr. Reddy's Laboratories' actions against Janssen regarding abiraterone).

    Trial decisions on the merits

    A number of further decisions on the merits were released in the fifth year, including as set out in our mid-year highlights:

  • Janssen v Pharmascience, Janssen v Apotex (paliperidone palmitate, INVEGA SUSTENNA) - Following the first summary trials under the Regulations, the trial Judge concluded Pharmascience and Apotex would induce infringement of claims for a dosing regimen. Appeals by both are pending. Subsequent to the summary trial, Pharmascience's invalidity defence was unsuccessful at trial.
  • Allergan v Apotex (risedronate sodium, ACTONEL DR) - Formulation claims "for use with or without food or beverage intake" held valid (not anticipated, not obvious, useful, sufficient, not overbroad), but not infringed (product monograph stated should be taken with food). Allergan's appeal is pending.
  • Merck Sharp & Dohme Corp v Pharmascience (sitagliptin phosphate monohydrate, JANUVIA) - Claim to R-enantiomer of the dihydrogen phosphate salt of sitagliptin in crystalline monohydrate form held valid (not obvious in view of the prior genus which included sitagliptin and its hydrochloride salt, not insufficient). Pharmascience's appeal is pending.
  • Janssen v Sandoz, Janssen v Apotex (macitentan, OPSUMIT) - In the Sandoz case, claims to macitentan in combination with a phosphodiesterase type-5 inhibitor to treat diseases where vasoconstriction is involved, including pulmonary arterial hypertension, were held valid (not obvious, utility soundly predicted, not overbroad, not insufficient). In the Apotex case, validity was not challenged, and Court held Apotex would induce infringement. Appeals by both are pending.
  • Federal Court of Appeal (FCA) decisions on the merits

  • Pharmascience v Teva (glatiramer acetate, COPAXONE, GLATECT) - FCA upheld the finding that claims to use of 40 mg glatiramer acetate administered by subcutaneous injection three times weekly for treatment of relapsing-remitting multiple sclerosis (802 patent) were valid (utility soundly predicted, not obvious). Infringement finding not challenged on appeal. Pharmascience has sought leave to appeal.
  • Pharmascience Inc v Bristol-Myers Squibb Canada Co (apixaban, ELIQUIS) - FCA upheld the finding that the two patents were valid: (1) the 202 patent, which claims apixaban, an anticoagulant, and the use of apixaban in the treatment of thromboembolic disorders (novel, not obvious, no double patenting and sufficient); and (2) the 171 patent, which claims tablet formulations of apixaban (not obvious, not ambiguous/overbroad).
  • Biogen Canada Inc v Pharmascience Inc, Taro (fampridine, FAMPYRA) - FCA upheld the finding that the patent relating to uses of fampridine sustained release compositions to treat multiple sclerosis was invalid (obvious).
  • Procedural matters

    In addition, a number of procedural decisions were released, including to provide interpretation on aspects of the Regulations:

  • The Federal Court of Appeal dismissed Merck's appeal and upheld a strict interpretation of the 30-day deadline for listing a patent on the Patent Register.
  • The Federal Court found the Minister of Health was reasonable in his interpretation of s. 5(1) of the Regulations as applying only to the drug identification number (DIN) specific version of the innovator's drug. As a result, JAMP was not a "second person" under the Regulations for its product SIMLANDI, a biosimilar of AbbVie's HUMIRA (adalimumab).
  • The Federal Court permitted Sandoz to add multiple grounds of invalidity six months into the proceeding, even though its NOA only asserted non-infringement and a Gillette defence, but only if the scheduled trial was adjourned to a future date and the 24-month stay was correspondingly extended.
  • Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.

    The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.


    1. Actions between the same parties in respect of the same innovator reference drug are considered one "set". The counts are provided as of the fifth-year anniversary, September 21, 2022.

    2. The number for 2020-2021 is lower than reported in our original fourth-year anniversary article, which included five section 8.2 actions.

    The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

    Ms Urszula Wojtyra
    Smart & Biggar
    1100-150 York Street
    ON M5H 3S5
    Tel: 4165935514
    Fax: 4165911690
    E-mail: Yliu@smartbiggar.ca
    URL: www.smartbiggar.ca

    © Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

    All news about NOVARTIS AG
    11/24Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study f..
    11/23Novartis, Medicines for Malaria Venture to Kick Off Phase 3 Study for Uncomplicated Mal..
    11/23Novartis : and Medicines for Malaria Venture announce decision to move to Phase 3 study fo..
    11/22Novartis' Sandoz, Teva Pharmaceutical Partner To Expand Biosimilars Production
    11/22Generic drugmakers Teva and Sandoz make major push to biosimilars
    11/22Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 da..
    11/22Teva Pharmaceutical Industries, Sandoz Plan to Boost Production of Biosimilars
    11/22NOVARTIS AG : Gets a Sell rating from Deutsche Bank
    11/22CORRECTED (OFFICIAL) -FOCUS-Generic drugmakers Teva and Sandoz make major push to biosi..
    11/21Teva Pharmaceutical Names Richard Francis as President, CEO
    More news
    Analyst Recommendations on NOVARTIS AG
    More recommendations
    Financials (USD)
    Sales 2022 51 251 M - -
    Net income 2022 8 751 M - -
    Net Debt 2022 7 355 M - -
    P/E ratio 2022 21,7x
    Yield 2022 3,75%
    Capitalization 189 B 189 B -
    EV / Sales 2022 3,83x
    EV / Sales 2023 3,84x
    Nbr of Employees 108 000
    Free-Float 87,1%
    Duration : Period :
    Novartis AG Technical Analysis Chart | MarketScreener
    Full-screen chart
    Technical analysis trends NOVARTIS AG
    Short TermMid-TermLong Term
    Income Statement Evolution
    Mean consensus OUTPERFORM
    Number of Analysts 26
    Last Close Price 87,73 $
    Average target price 90,70 $
    Spread / Average Target 3,39%
    EPS Revisions
    Managers and Directors
    Vasant Narasimhan Chief Executive Officer
    Harry Werner Kirsch Chief Financial Officer
    Hans J÷rg Reinhardt Non-Executive Chairman
    Shreeram Aradhye Chief Medical Officer
    Steffen Lang President-Operations
    Sector and Competitors
    1st jan.Capi. (M$)
    NOVARTIS AG3.43%188 707
    JOHNSON & JOHNSON3.61%463 391
    ELI LILLY AND COMPANY30.95%347 052
    ABBVIE INC.17.89%282 189
    PFIZER, INC.-16.66%276 231
    MERCK & CO., INC.40.27%272 555